ReviewJournal of nephrology2019
Subclinical AKI: ready for primetime in clinical practice?
Review in Journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Cryptic and Overt Acute Kidney Injury Share Biomarker Characteristics in Pediatric Acute Respiratory Distress Syndrome.Critical care explorations · 2026Observational
- Tubular Damage Biomarkers Are a Useful Tool for Identifying Early Renal Injury in Long COVID.International journal of molecular sciences · 2026Article
- Plasma NGAL-detected kidney injury following paediatric spine surgery: role of intraoperative hypotension.BMC nephrology · 2026Article
- Antiproteinuric effect of dapagliflozin attenuates tubule-interstitial injury development in subclinical acute kidney injury animal model.Frontiers in pharmacology · 2026Article
- Serial Combination of Toxic and Ischemic Renal Damages Causes Subsequent Chronic, Irreversible, and Progressive Renal Disease in Rats.International journal of molecular sciences · 2025Article
- Effects of Anethole on Renal Function of Swiss Mice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers.Kidney international reports · 2025Article
- Acute Kidney Injury in Children: A Focus for the General Pediatrician.Children (Basel, Switzerland) · 2024Review
- A Clinical Study on Urinary Clusterin and Cystatin B in Dogs with Spontaneous Acute Kidney Injury.Veterinary sciences · 2024Article
- Longitudinal NGAL and cystatin C plasma profiles present a high level of heterogeneity in a mixed ICU population.BMC nephrology · 2024Article
- Urinary Collectrin as Promising Biomarker for Acute Kidney Injury in Patients Undergoing Cardiac Surgery.Biomedicines · 2023Article
- New Issues With Neutrophil Gelatinase-associated Lipocalin in Acute Kidney Injury.Annals of laboratory medicine · 2023Article
- Acute and chronic kidney complications in children with type 1 diabetes mellitus.Pediatric nephrology (Berlin, Germany) · 2023Review
- Acute Kidney Injury: Medical Causes and Pathogenesis.Journal of clinical medicine · 2023Review
- Subclinical Acute Kidney Injury in COVID-19: Possible Mechanisms and Future Perspectives.International journal of molecular sciences · 2022Review
- Diagnosis of Cardiac Surgery-Associated Acute Kidney Injury: State of the Art and Perspectives.Journal of clinical medicine · 2022Review
- The attributable mortality of new-onset acute kidney injury among critically ill patients: a propensity-matched analysis based on a multicentre prospective cohort study.International urology and nephrology · 2022Article
- Identifying Common Molecular Mechanisms in Experimental and Human Acute Kidney Injury.Seminars in nephrology · 2022Review
- KLF4 initiates sustained YAP activation to promote renal fibrosis in mice after ischemia-reperfusion kidney injury.Acta pharmacologica Sinica · 2021Article
- Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment: The Physio-Pathological Conditions for the Perfect Murder.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been considerable progress over the last decade in the standardization of the acute kidney injury (AKI) definition with the publication of the RIFLE, AKIN, KDIGO and ERBP classification criteria. However, these classification criteria still rely on imperfect parameters such as serum creatinine and urinary output. The use of timed urine collections, kinetic eGFR (estimated glomerular filtration rate), real time measurement of GFR and direct measures of tubular damage can theoretically aid in a more timely diagnosis of AKI and improve patients' outcome. There has been an extensive search for new biomarkers indicative of structural tubular damage but it remains controversial whether these new markers should be included in the current classification criteria. The use of these markers has also led to the creation of a new concept called subclinical AKI, a condition where there is an increase in biomarkers but without clinical AKI, defined as an increase in serum creatinine and/or a decrease in urinary output. In this review we provide a framework on how to critical appraise biomarker research and on how to position the concept of subclinical AKI. The evaluation of biomarker performance and the usefulness of the concept 'subclinical AKI' requires careful consideration of the context these biomarkers are used in (clinical versus research setting) and the goal we want to achieve (risk assessment versus prediction versus early diagnosis versus prognostication). It remains currently unknown whether an increase in biomarkers levels without functional repercussion is clinically relevant and whether including biomarkers in classification criteria will improve patients' outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.